Search Results for "corticosteroids, topical"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for corticosteroids, topical. Results 41 to 50 of 125 total matches.
Budesonide (Entocort EC) For Crohn's Disease
The Medical Letter on Drugs and Therapeutics • Jan 21, 2002 (Issue 1122)
Letter 1999; 41:61).
CONCLUSION — Oral budesonide (Entocort EC), a corticosteroid that offers topical ...
Budesonide (Entocort EC AstraZeneca), a locally active glucocorticosteriod widely used for inhalation treatment of allergic rhinitis and asthma (Medical Letter 2000; 42:19), has been approved for oral treatment of mild to moderate active Crohn's disease involving the ileum and/or ascending colon. Both oral budesonide and budesonide enemas have been available for years in Europe and Canada for treatment of inflammatory bowel disease.
Fluticasone Propionate Nasal Spray for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Jan 20, 1995 (Issue 940)
and children more than 12 years old.
PHARMACOLOGY — Topical application of corticosteroids decreases ...
An intranasal spray formulation of the corticosteroid fluticasone propionate (floo tik a sone; Flonase - Allen & Hanburys) has been approved by the US Food and Drug Administration for treatment of seasonal and perennial allergic rhinitis in adults and children more than 12 years old.
Nebulized Budesonide For Asthma in Children
The Medical Letter on Drugs and Therapeutics • Jan 22, 2001 (Issue 1096)
budesonide is generally well tolerated. Topical corticosteroids can cause oral candidiasis, hoarseness ...
The FDA has approved a nebulized suspension of the corticosteroid budesonide for maintenance treatment of persistent asthma in children one to eight years old.
Drugs for Osteoarthritis
The Medical Letter on Drugs and Therapeutics • Apr 20, 2020 (Issue 1596)
is
ineffective, switching to another may provide better
pain control. Topical NSAIDs should be considered ...
Many different drugs are used for treatment of
osteoarthritis pain, but none of them prevent
progression of the disease. Nonpharmacologic
approaches including weight management, exercise,
tai chi, physical therapy, assistive devices, and total
joint arthroplasty can also be used. The American
College of Rheumatology (ACR) has published new
guidelines for the management of osteoarthritis of the
hip, hand, and knee.
Ketorolac for Seasonal Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Sep 17, 1993 (Issue 905)
. Topical corticosteroids are effective for treatment of this condition, but
prolonged use can cause ...
Ketorolac (kee' toe role ak) tromethamine 0.5%, a nonsteroidal anti-inflammatory drug (NSAID) previously available for parenteral and oral administration (Toradol - Medical Letter, 32:79, 1990), has now been approved for ophthalmic use (Acular - Allergan, Fisons) to relieve itching in seasonal allergic conjunctivitis. NSAIDs decrease prostaglandin concentrations in the eye, which theoretically might contribute to a decrease in itching. Several other NSAIDs are available for ophthalmic use in the USA, but none is marketed for this indication. Flurbiprofen (Ocufen) and suprofen (Profenal) ...
Alefacept (Amevive) For Treatment of Psoriasis
The Medical Letter on Drugs and Therapeutics • Apr 14, 2003 (Issue 1154)
is usually treated with topical
corticosteroids or tars and anthralin preparations, which may be combined ...
Alefacept (a le' fa sept; Amevive - Biogen) has been approved by the FDA for parenteral treatment of adults with moderate to severe chronic plaque psoriasis.
Bepotastine (Bepreve) - An Ophthalmic H1-Antihistamine
The Medical Letter on Drugs and Therapeutics • Feb 08, 2010 (Issue 1331)
(Bepreve – ISTA Pharmaceuticals), an H
1
-antihistamine, has been approved by the FDA for topical ...
Bepotastine besilate 1.5% ophthalmic solution (Bepreve - ISTA Pharmaceuticals), an H1-antihistamine, has been approved by the FDA for topical treatment of itching associated with allergic conjunctivitis in patients ≥2 years old. Bepotastine was first developed in an oral systemic formulation and has been used as such for treatment of allergic rhinitis in Japan.
OTC Fluticasone Nasal Spray for Allergic Rhinitis
The Medical Letter on Drugs and Therapeutics • Mar 30, 2015 (Issue 1465)
concomitantly, and sometimes a topical
corticosteroid for atopic dermatitis as well. Additive
effects could ...
The nasal spray formulation of the corticosteroid
fluticasone propionate is now available over the
counter (OTC) as Flonase Allergy Relief (GSK) in
the same strength as the prescription product
(Flonase, and generics) for patients ≥4 years old with
seasonal or perennial allergic rhinitis. It is the second
corticosteroid nasal spray to become available OTC;
triamcinolone acetonide (Nasacort Allergy 24HR) was
the first. Unlike prescription Flonase, the OTC product
is FDA-approved for reduction of ocular as well as
nasal symptoms. Brand-name prescription Flonase
has been...
ColciGel - A Homeopathic Colchicine Gel for Gout
The Medical Letter on Drugs and Therapeutics • Jan 04, 2016 (Issue 1485)
courses of an oral or parenteral corticosteroid
such as prednisone or methylprednisolone are also ...
Homeopathic drugs characteristically consist of very
large dilutions of "proven" substances. Serial dilutions
of 1:10 are designated by the Roman numeral X.
ColciGel (Gensco), a prescription homeopathic
gel containing a 10,000-fold dilution of colchicine
(colchicinum 4X), is now being marketed for topical
treatment and prophylaxis of gout.
Three Drugs for Atopic Dermatitis (Adbry, Cibinqo, and Rinvoq)
The Medical Letter on Drugs and Therapeutics • Apr 03, 2023 (Issue 1673)
10.9% 11.4% 25.0% 21.4%
ECZTRA 3 (32 wks; with topical corticosteroids; n=378)7
Tralokinumab 300 mg ...
The subcutaneously injected interleukin-13 (IL-13)
antagonist tralokinumab-ldrm (Adbry – Leo) and
the oral Janus kinase (JAK) inhibitors abrocitinib
(Cibinqo – Pfizer) and upadacitinib (Rinvoq – Abbvie)
have been approved by the FDA for treatment of
moderate to severe atopic dermatitis.
Med Lett Drugs Ther. 2023 Apr 3;65(1673):51-5 doi:10.58347/tml.2023.1673b | Show Introduction Hide Introduction